From basic research to the bedside: efficacy of topical treatment with pseudocatalase PC-KUS in 71 children with vitiligo

Authors

  • Karin U. Schallreuter MD,

    1. From Clinical and Experimental Dermatology, Department of Biomedical Sciences, University of Bradford, Bradford, UK, and Institute for Pigmentary Disorders e.V. (in Association with the Ernst-Moritz-Arndt University Greifswald, Greifswald, Germany and University of Bradford, UK)
    Search for more papers by this author
  • Christian Krüger PhD,

    1. From Clinical and Experimental Dermatology, Department of Biomedical Sciences, University of Bradford, Bradford, UK, and Institute for Pigmentary Disorders e.V. (in Association with the Ernst-Moritz-Arndt University Greifswald, Greifswald, Germany and University of Bradford, UK)
    Search for more papers by this author
  • Brigitte A. Würfel MD,

    1. From Clinical and Experimental Dermatology, Department of Biomedical Sciences, University of Bradford, Bradford, UK, and Institute for Pigmentary Disorders e.V. (in Association with the Ernst-Moritz-Arndt University Greifswald, Greifswald, Germany and University of Bradford, UK)
    Search for more papers by this author
  • Angela Panske MSc,

    1. From Clinical and Experimental Dermatology, Department of Biomedical Sciences, University of Bradford, Bradford, UK, and Institute for Pigmentary Disorders e.V. (in Association with the Ernst-Moritz-Arndt University Greifswald, Greifswald, Germany and University of Bradford, UK)
    Search for more papers by this author
  • John M. Wood PhD

    1. From Clinical and Experimental Dermatology, Department of Biomedical Sciences, University of Bradford, Bradford, UK, and Institute for Pigmentary Disorders e.V. (in Association with the Ernst-Moritz-Arndt University Greifswald, Greifswald, Germany and University of Bradford, UK)
    Search for more papers by this author


Karin U. Schallreuter Professor, MD Clinical and Experimental Dermatology Department of Biomedical Sciences University of Bradford Richmond Road Bradford BD7 1DP UK
E-mail: K.Schallreuter@Bradford.ac.uk

Abstract

Background  The epidermal accumulation of hydrogen peroxide (H2O2) has been documented in vitiligo.

Aim  To assess the effect on disease cessation and repigmentation of the reduction/removal of H2O2 using low-dose, narrow-band, ultraviolet-B (UV-B)-activated pseudocatalase PC-KUS in 71 children with vitiligo.

Methods  This uncontrolled and retrospective study included 45 girls and 26 boys (mean age, 10.3 years) who applied topical PC-KUS twice daily to the entire body surface without narrow-band UV-B dose increments. The affected body areas were documented by special photography at the first visit and after 8–12 months. The response was evaluated by two independent physicians as > 75% vs. < 75% total repigmentation of the face/neck, trunk, extremities, and hands/feet. Generalized (n = 61) and segmental (n = 10) vitiligo were evaluated as different entities. The effect of total-body, low-dose, narrow-band UV-B (0.15 mJ/cm2) monotherapy once daily without any increments and without application of PC-KUS was tested over 6 months in 10 children with vitiligo vulgaris (mean age, 8.4 years).

Results  One hundred per cent cessation was observed in 70 of the 71 children. More than 75% repigmentation was achieved in 66 of 71 patients on the face/neck, 48 of 61 on the trunk, and 40 of 55 on the extremities; however, repigmentation on the hands/feet was disappointing (five of 53). The response was independent of skin color, age of onset, duration of disease, other demographic features, and previous treatments. The follow-up after narrow-band UV-B monotherapy showed no significant repigmentation in all areas. Seven of 10 patients showed progression of their vitiligo.

Conclusion  A reduction in epidermal H2O2 using low-dose, narrow-band UV-B-activated pseudocatalase PC-KUS is an effective treatment for childhood vitiligo which can be safely performed at home.

Ancillary